Microvascular modifications in diabetic retinopathy

Current Diabetes Reports

Volumn 11, Issue 4, 2011, Pages 253-264

  Durham, Jennifer T ^a   Herman, Ira M ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

Adenovirus AAV; Angiogenesis; Cytoskeleton; Diabetic retinopathy; Endothelial cell; Microvascular modifications; PEDF; Pericyte; PPE1; VEGF

Indexed keywords

ANGIOSTATIN; AUTACOID; BEVACIZUMAB; ENDOGLIN; ENDOSTATIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GELATINASE A; GELATINASE B; GROWTH FACTOR; NANOPARTICLE; NONSTEROID ANTIINFLAMMATORY AGENT; PARVOVIRUS VECTOR; PEGAPTANIB; RANIBIZUMAB; RETINOSTAT; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; CAPILLARY BASEMENT MEMBRANE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; HELPER VIRUS; HUMAN; INFLAMMATION; LASER COAGULATION; NONHUMAN; PATHOPHYSIOLOGY; PERICYTE; RETINA BLOOD FLOW; RETINA BLOOD VESSEL; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; REVIEW; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VITRECTOMY;

ANGIOGENESIS INHIBITORS; ANIMALS; DIABETIC RETINOPATHY; ENDOTHELIAL CELLS; HUMANS; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80051597186     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-011-0204-0     Document Type: Review

References (160)

1. TM Curtis TA Gardiner AW Stitt 2009 Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis? Eye (Lond) 23 1496 1508 1:STN:280:DC%2BD1MvovVygsg%3D%3D This is a cogent review on DR.
2. DA Antonetti AJ Barber SK Bronson WM Freeman TW Gardner LS Jefferson, et al. 2006 Diabetic retinopathy: seeing beyond glucose-induced microvascular disease Diabetes 55 2401 2411 16936187 1:CAS:528:DC%2BD28XpsVOrtrs%3D (Pubitemid 44871140)
3. JH Kim JH Kim HO Jun YS Yu KW Kim 2010 Inhibition of protein Kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy Am J Pathol 176 1517 1524 20110406 1:CAS:528:DC%2BC3cXktVOitr8%3D
4. Q Zhu X Xu X Xia Q Gu PC Ho 2005 Role of protein Kinase C on the alteration of retinal endothelin-1 in streptozotocin-induced diabetic rats Exp Eye Res 81 200 206 16080914 1:CAS:528:DC%2BD2MXntVGnsb8%3D (Pubitemid 41080102)
5. AM Joussen V Poulaki ML Le K Koizumi C Esser H Janicki, et al. 2004 A central role for inflammation in the pathogenesis of diabetic retinopathy FASEB J 18 1450 1452 15231732 1:CAS:528:DC%2BD2cXntlKktLs%3D (Pubitemid 39561611)
6. AM Joussen V Poulaki W Qin B Kirchhof N Mitsiades SJ Wiegand, et al. 2002 Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo Am J Pathol 160 501 509 11839570 1:CAS:528:DC%2BD38XitVCksL0%3D (Pubitemid 34160327)
7. DS McLeod DJ Lefer C Merges GA Lutty 1995 Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid Am J Pathol 147 642 653 7545873 1:CAS:528:DyaK2MXoslKjsbw%3D
8. FC Barouch K Miyamoto JR Allport K Fujita SE Bursell LP Aiello, et al. 2000 Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes Invest Ophthalmol Vis Sci 41 1153 1158 10752954 1:STN:280:DC%2BD3c3hsVKhug%3D%3D (Pubitemid 30187554)
9. H Sone Y Kawakami Y Okuda S Kondo M Hanatani H Suzuki, et al. 1996 Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells Biochem Biophys Res Commun 221 193 198 8660335 1:CAS:528:DyaK28XitlCgtrY%3D (Pubitemid 26136446)
10. AM Abu el Asrar D Maimone PH Morse S Gregory AT Reder 1992 Cytokines in the vitreous of patients with proliferative diabetic retinopathy Am J Ophthalmol 114 731 736 1463043 1:STN:280:DyaK3s%2FpvVartA%3D%3D
11. N Demircan BG Safran M Soylu AA Ozcan S Sizmaz 2006 Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy Eye (Lond) 20 1366 1369 1:CAS:528: DC%2BD28Xht12ktbjM (Pubitemid 44921137)
12. S Roy E Cagliero M Lorenzi 1996 Fibronectin overexpression in retinal microvessels of patients with diabetes Invest Ophthalmol Vis Sci 37 258 266 8603829 1:STN:280:DyaK287ptVeksA%3D%3D (Pubitemid 26057051)
13. A Das RN Frank NL Zhang E Samadani 1990 Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening-prevention by an aldose reductase inhibitor Exp Eye Res 50 269 280 2108050 1:CAS:528:DyaK3cXhsFWrs7s%3D (Pubitemid 20081140)
14. S Vasan P Foiles H Founds 2003 Therapeutic potential of breakers of advanced glycation end product-protein crosslinks Arch Biochem Biophys 419 89 96 14568012 1:CAS:528:DC%2BD3sXotVCjurY%3D (Pubitemid 37272162)
15. A Orlidge PA D'Amore 1987 Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells J Cell Biol 105 1455 1462 3654761 1:STN:280:DyaL1c%2Fgslyksg%3D%3D (Pubitemid 18029870)
16. A RayChaudhury PA D'Amore 1991 Endothelial cell regulation by transforming growth factor-beta J Cell Biochem 47 224 229 1724244 1:CAS:528:DyaK38XjsVKhsQ%3D%3D
17. LE Benjamin I Hemo E Keshet 1998 A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF Development 125 1591 1598 9521897 1:CAS:528:DyaK1cXjslemsLg%3D (Pubitemid 28256727)
18. T Kuwabara DG Cogan 1963 Retinal vascular patterns. VI. Mural cells of the retinal capillaries Arch Ophthalmol 69 492 502 13927676 1:STN:280: DyaF387hvFeitg%3D%3D
19. HP Hammes 2005 Pericytes and the pathogenesis of diabetic retinopathy Horm Metab Res 37 Suppl 1 39 43 15918109
20. W Li M Yanoff X Liu X Ye 1997 Retinal capillary pericyte apoptosis in early human diabetic retinopathy Chin Med J (Engl) 110 659 663 1:STN:280:DyaK1czgs1aksQ%3D%3D (Pubitemid 127510208)
21. WG Robison Jr ML McCaleb LG Feld OE Michaelis 4th N Laver M Mercandetti 1991 Degenerated intramural pericytes ('ghost cells') in the retinal capillaries of diabetic rats Curr Eye Res 10 339 350 1829996
22. P Geraldes J Hiraoka-Yamamoto M Matsumoto A Clermont M Leitges A Marette, et al. 2009 Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy Nat Med 15 1298 1306 19881493 1:CAS:528:DC%2BD1MXhtlers7nK This is an intriguing report describing a platelet-derived growth factor-regulated mechanism controlling pericyte apoptosis following hyperglycemia.
23. F Pfister Y Feng F vom Hagen S Hoffmann G Molema JL Hillebrands, et al. 2008 Pericyte migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy Diabetes 57 2495 2502 18559662 1:CAS:528:DC%2BD1cXhtFSrtrnL
24. T Sato R Haimovici R Kao AF Li S Roy 2002 Downregulation of Connexin 43 expression by high glucose reduces gap junction activity in microvascular endothelial cells Diabetes 51 1565 1571 11978657 1:CAS:528:DC%2BD38XjtlGmtbk%3D (Pubitemid 34826626)
25. MW Bobbie S Roy K Trudeau SJ Munger AM Simon S Roy 2010 Reduced Connexin 43 expression and its effect on the development of vascular lesions in retinas of diabetic mice Invest Ophthalmol Vis Sci 51 3758 3763 20130277
26. M Hellstrom H Gerhardt M Kalen X Li U Eriksson H Wolburg, et al. 2001 Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis J Cell Biol 153 543 553 11331305 1:CAS:528:DC%2BD3MXjt1alsL4%3D (Pubitemid 34280141)
27. T Murakami K Suzuma H Takagi M Kita H Ohashi D Watanabe, et al. 2006 Time-lapse imaging of vitreoretinal angiogenesis originating from both quiescent and mature vessels in a novel ex vivo system Invest Ophthalmol Vis Sci 47 5529 5536 17122145 (Pubitemid 46723806)
28. ME Kutcher AY Kolyada HK Surks IM Herman 2007 Pericyte Rho GTPase mediates both pericyte contractile phenotype and capillary endothelial growth state Am J Pathol 171 693 701 17556591 1:CAS:528:DC%2BD2sXpsFahsLw%3D (Pubitemid 47344700)
29. M Kotecki AS Zeiger KJ Van Vliet IM Herman 2010 Calpain- and talin-dependent control of microvascular pericyte contractility and cellular stiffness Microvasc Res 80 339 348 20709086 1:CAS:528:DC%2BC3cXhsVWmtbnI Using cell-penetrating calpain inhibitors in conjunction with cytoskeletal protein overexpression, results reveals how pericyte mechanical stiffness is altered downstream of calpain function.
30. • Lee S, Zeiger A, Maloney J, Maciej K, Van Vliet K, Herman IM. Pericyte actomyosin-mediated contraction at the cell-material interface can modulate the microvascular niche. 2010;22:1-11. This report explores the critical role that the cytoskeleton plays in regulating pericyte biomechanical forces.
31. J Folkman A Moscona 1978 Role of cell shape in growth control Nature 273 345 349 661946 1:CAS:528:DyaE1cXlslOju70%3D (Pubitemid 8344174)
32. A Mammoto S Huang K Moore P Oh DE Ingber 2004 Role of RhoA, mDia, and ROCK in cell shape-dependent control of the Skp2-p27kip1 pathway and the G1/S transition J Biol Chem 279 26323 26330 15096506 1:CAS:528:DC%2BD2cXkvVWgsL8%3D (Pubitemid 38798782)
33. A Mammoto KM Connor T Mammoto CW Yung D Huh CM Aderman, et al. 2009 A mechanosensitive transcriptional mechanism that controls angiogenesis Nature 457 1103 1108 19242469 1:CAS:528:DC%2BD1MXitlGlu78%3D
34. K Ghosh CK Thodeti AC Dudley A Mammoto M Klagsbrun DE Ingber 2008 Tumor-derived endothelial cells exhibit Aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro Proc Natl Acad Sci USA 105 11305 11310 18685096 1:CAS:528:DC%2BD1cXhtVShu7zM
35. J Tang S Mohr YD Du TS Kern 2003 Non-uniform distribution of lesions and biochemical abnormalities within the retina of diabetic humans Curr Eye Res 27 7 13 12868004 1:STN:280:DC%2BD3szjsFajsg%3D%3D (Pubitemid 36936342)
36. TS Kern RL Engerman 1995 Vascular lesions in diabetes are distributed non-uniformly within the retina Exp Eye Res 60 545 549 7615020 1:CAS:528:DyaK2MXlvVOqtr8%3D
37. Brunner S, Hoellerl F, Schmid-Kubista KE, Zeiler F, Schernthaner G, Binder S, Schernthaner GH. Circulating angiopoietic cells and diabetic retinopathy in T2DM patients with and without macrovascular disease. Invest Ophthalmol Vis Sci. 2011.
38. A Dardik L Chen J Frattini H Asada F Aziz FA Kudo, et al. 2005 Differential effects of orbital and laminar shear stress on endothelial cells J Vasc Surg 41 869 880 15886673 (Pubitemid 40693811)
39. DC Darland LJ Massingham SR Smith E Piek M Saint-Geniez PA D'Amore 2003 Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival Dev Biol 264 275 288 14623248 1:CAS:528:DC%2BD3sXovVehs7w%3D (Pubitemid 37393463)
40. Early Treatment Diabetic Retinopathy Study Research Group 1991 Early photocoagulation for diabetic retinopathy. ETDRS Report Number 9 Ophthalmology 98 66 785
41. The Diabetic Retinopathy Study Research Group 1981 Photocoagulation treatment of proliferative diabetic retinopathy. Clinical Application of Diabetic Retinopathy Study (DRS) Findings, DRS Report Number 8 Ophthalmology 88 583 600
42. RC Kleiner MJ Elman RP Murphy FL Ferris 3rd 1988 Transient severe visual loss after panretinal photocoagulation Am J Ophthalmol 106 298 306 3421291 1:STN:280:DyaL1czjvVKqsQ%3D%3D
43. G Kleinmann D Hauser E Schechtman G Landa A Bukelman A Pollack 2008 Vitreous hemorrhage in diabetic eyes previously treated with panretinal photocoagulation Int Ophthalmol 28 29 34 17619829 (Pubitemid 351308682)
44. H Lewis AP Schachat MH Haimann JA Haller P Quinlan MA von Fricken, et al. 1990 Choroidal neovascularization after laser photocoagulation for diabetic macular edema Ophthalmology 97 503 10 1691477 1:STN:280:DyaK3c3itFCrtg%3D%3D discussion 510-1
45. AA Dosso ER Bonvin Y Morel A Golay JP Assal PM Leuenberger 1996 Risk factors associated with contrast sensitivity loss in diabetic patients Graefes Arch Clin Exp Ophthalmol 234 300 305 8740250 1:STN:280:DyaK28zhtVSqsw%3D%3D (Pubitemid 26134055)
46. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 4938153 1:STN:280:DyaE38%2FgvVCqsQ%3D%3D
47. A Patz 1984 Retinal neovascularisation: early contributions of professor michaelson and recent observations Br J Ophthalmol 68 42 46 6197084 1:STN:280:DyaL2c%2FotVeguw%3D%3D (Pubitemid 15134740)
48. DR Senger L Van de Water LF Brown JA Nagy KT Yeo TK Yeo, et al. 1993 Vascular permeability factor (VPF, VEGF) in tumor biology Cancer Metastasis Rev 12 303 324 8281615 1:CAS:528:DyaK2cXnsVejug%3D%3D (Pubitemid 23293287)
49. DR Senger SJ Galli AM Dvorak CA Perruzzi VS Harvey HF Dvorak 1983 Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 219 983 985 6823562 1:STN:280:DyaL3s7hvF2mtw%3D%3D
50. DW Leung G Cachianes WJ Kuang DV Goeddel N Ferrara 1989 Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 1306 1309 2479986 1:CAS:528:DyaK3cXls1GltLo%3D (Pubitemid 20066716)
51. PJ Keck SD Hauser G Krivi K Sanzo T Warren J Feder, et al. 1989 Vascular permeability factor, an endothelial cell mitogen related to PDGF Science 246 1309 1312 2479987 1:CAS:528:DyaK3cXkslGksLc%3D (Pubitemid 20066717)
52. JW Miller AP Adamis DT Shima PA D'Amore RS Moulton MS O'Reilly, et al. 1994 Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model Am J Pathol 145 574 584 7521577 1:CAS:528:DyaK2cXmvFygtrs%3D (Pubitemid 24285965)
53. LP Aiello RL Avery PG Arrigg BA Keyt HD Jampel ST Shah, et al. 1994 Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 1480 1487 7526212 1:STN:280:DyaK2M%2FlvFamsA%3D%3D (Pubitemid 24356306)
54. N Ferrara KJ Hillan W Novotny 2005 Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Biochem Biophys Res Commun 333 328 335 15961063 1:CAS:528:DC%2BD2MXlsVChtLs%3D (Pubitemid 40848295)
55. RL Avery DJ Pieramici MD Rabena AA Castellarin MA Nasir MJ Giust 2006 Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 363 372.e5 16458968
56. RF Spaide K Laud HF Fine JM Klancnik Jr CB Meyerle LA Yannuzzi, et al. 2006 Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration Retina 26 383 390 16603955 (Pubitemid 44197628)
57. GP Giuliari DA Guel MA Cortez RT Cortez 2010 Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary Can J Ophthalmol 45 501 508 20648074 This is a comprehensive review of anti-VEGF therapeutics.
58. EW Ng AP Adamis 2006 Anti-VEGF aptamer (Pegaptanib) therapy for ocular vascular diseases Ann NY Acad Sci 1082 151 171 17145936 1:CAS:528: DC%2BD2sXmvFOnsQ%3D%3D (Pubitemid 44955460)
59. ET Cunningham Jr AP Adamis M Altaweel LP Aiello NM Bressler DJ D'Amico, et al. 2005 A phase ii randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema Ophthalmology 112 1747 1757 16154196
60. G Querques AV Bux AR Fusco C Iaculli N Delle Noci 2009 Pegaptanib sodium versus pegaptanib sodium combined with macular laser photocoagulation or laser alone for diabetic macular edema J Ophthalmol 2009 672178 20339449 1:STN:280:DC%2BC3c3hsVaiug%3D%3D
61. G Querques AV Bux D Martinelli C Iaculli ND Noci 2009 Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema Acta Ophthalmol 87 623 630 19678810 1:CAS:528:DC%2BD1MXht1Gnt73J
62. AP Adamis M Altaweel NM Bressler ET Cunningham Jr MD Davis M Goldbaum, et al. 2006 Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals Ophthalmology 113 23 28 16343627 (Pubitemid 43021723)
63. VH Gonzalez GP Giuliari RM Banda DA Guel 2009 Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy Br J Ophthalmol 93 1474 1478 19692371 1:STN:280:DC%2BD1MjhtFeitQ%3D%3D
64. E Mendrinos G Donati CJ Pournaras 2009 Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib Acta Ophthalmol 87 683 684 19021597
65. D Hornan N Edmeades R Krishnan J Khan J Lochhead 2010 Use of pegaptanib for recurrent and non-clearing vitreous haemorrhage in proliferative diabetic retinopathy Eye (Lond) 24 1315 1319 1:CAS:528:DC%2BC3cXhtVajt73P
66. R Jorge RA Costa D Calucci LP Cintra IU Scott 2006 Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE Study) Retina 26 1006 1013 17151487 (Pubitemid 44973219)
67. C Haritoglou D Kook A Neubauer A Wolf S Priglinger R Strauss, et al. 2006 Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema Retina 26 999 1005 17151486 (Pubitemid 44973218)
68. JF Arevalo JG Sanchez L Wu M Maia AA Alezzandrini M Brito, et al. 2009 Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months Ophthalmology 116 1488 97 19545900 1497.e1
69. JF Arevalo JG Sanchez AF Lasave L Wu M Maia S Bonafonte, et al. 2010 Intravitreal bevacizumab (Avastin((R))) for diabetic retinopathy at 24-months: the 2008 Juan Verdaguer-Planas lecture Curr Diabetes Rev 6 313 322 20594160 1:CAS:528:DC%2BC3cXht1CjsLzM
70. RL Avery J Pearlman DJ Pieramici MD Rabena AA Castellarin MA Nasir, et al. 2006 Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy Ophthalmology 113 1695.e1 1695.15
71. R Kohno Y Hata Y Mochizuki R Arita S Kawahara T Kita, et al. 2010 Histopathology of neovascular tissue from eyes with proliferative diabetic retinopathy after intravitreal bevacizumab injection Am J Ophthalmol 150 223 229.e1 20542485 1:CAS:528:DC%2BC3cXpsFCjsb8%3D
72. T Hattori H Shimada H Nakashizuka Y Mizutani R Mori M Yuzawa 2010 Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy Retina 30 761 764 20453802
73. M Modarres H Nazari KG Falavarjani M Naseripour M Hashemi MM Parvaresh 2009 Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy Eur J Ophthalmol 19 848 852 19787608
74. WB Cho SB Oh JW Moon HC Kim 2009 Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy Retina 29 516 522 19262436
75. L Wu MA Martinez-Castellanos H Quiroz-Mercado JF Arevalo MH Berrocal ME Farah, et al. 2008 Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES) Graefes Arch Clin Exp Ophthalmol 246 81 87 17674014 1:CAS:528:DC%2BD2sXhtlaqsbbP (Pubitemid 350167096)
76. O Sawada H Kawamura M Kakinoki T Sawada M Ohji 2007 Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy Arch Ophthalmol 125 1363 1366 17923544 1:CAS:528:DC%2BD2sXht1aqurrP (Pubitemid 47606601)
77. DW Chun JS Heier TM Topping JS Duker JM Bankert 2006 A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema Ophthalmology 113 1706 1712 17011952 (Pubitemid 44442451)
78. QD Nguyen S Tatlipinar SM Shah JA Haller E Quinlan J Sung, et al. 2006 Vascular endothelial growth factor is a critical stimulus for diabetic macular edema Am J Ophthalmol 142 961 969 17046701 1:CAS:528:DC%2BD28Xht12msLfE
79. Diabetic Retinopathy Clinical Research Network MJ Elman LP Aiello RW Beck NM Bressler SB Bressler, et al. 2010 Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 1064 1077.e35 20427088
80. M Ratner 2004 Genentech discloses safety concerns over avastin Nat Biotechnol 22 1198 15470443 1:CAS:528:DC%2BD2cXotFGqs7Y%3D
81. M Saint-Geniez T Kurihara E Sekiyama AE Maldonado PA D'Amore 2009 An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris Proc Natl Acad Sci USA 106 18751 18756 19841260 1:CAS:528:DC%2BD1MXhsVKmtL7N In this report, results reveal that retinal pigment epithelium-synthesized VEGF is critical for normal maintenance of the choriocapillaris.
82. M Saint-Geniez AS Maharaj TE Walshe BA Tucker E Sekiyama T Kurihara, et al. 2008 Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors PLoS ONE 3 e3554 18978936
83. AL Magnussen ES Rennel J Hua HS Bevan N Beazley Long C Lehrling, et al. 2010 VEGF-A165b is cytoprotective and antiangiogenic in the retina Invest Ophthalmol Vis Sci 51 4273 4281 20237249
84. RM Perrin O Konopatskaya Y Qiu S Harper DO Bates AJ Churchill 2005 Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor Diabetologia 48 2422 2427 16193288 1:CAS:528:DC%2BD2MXht1Skt7vM (Pubitemid 41618935)
85. O Konopatskaya AJ Churchill SJ Harper DO Bates TA Gardiner 2006 VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice Mol Vis 12 626 632 16735996 1:CAS:528: DC%2BD28XntVelsrY%3D (Pubitemid 43786776)
86. AM Joussen V Poulaki N Mitsiades B Kirchhof K Koizumi S Dohmen, et al. 2002 Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression FASEB J 16 438 440 11821258 1:CAS:528: DC%2BD38XhvValu70%3D
87. KM Connor JP SanGiovanni C Lofqvist CM Aderman J Chen A Higuchi, et al. 2007 Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis Nat Med 13 868 873 17589522 1:CAS:528:DC%2BD2sXnsFWmtrw%3D (Pubitemid 47038185)
88. PA Campochiaro 2007 Molecular targets for retinal vascular diseases J Cell Physiol 210 575 581 17133346 1:CAS:528:DC%2BD2sXht1ejtbw%3D (Pubitemid 46185026)
89. BO Boehm G Lang O Volpert PM Jehle A Kurkhaus S Rosinger, et al. 2003 Low content of the natural ocular anti-angiogenic agent Pigment Epithelium-Derived Factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy Diabetologia 46 394 400 12687338 1:CAS:528:DC%2BD3sXksVWjtbs%3D (Pubitemid 36547595)
90. EJ Duh HS Yang JA Haller E De Juan MS Humayun P Gehlbach, et al. 2004 Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis Am J Ophthalmol 137 668 674 15059706 1:CAS:528:DC%2BD2cXisl2rurk%3D (Pubitemid 38446681)
91. PA Campochiaro QD Nguyen SM Shah ML Klein E Holz RN Frank, et al. 2006 Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial Hum Gene Ther 17 167 176 16454650 1:CAS:528:DC%2BD28XpvV2itw%3D%3D (Pubitemid 43262032)
92. C Kanthou GM Tozer 2009 Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies Int J Exp Pathol 90 284 294 19563611 1:CAS:528:DC%2BD1MXotV2isr4%3D This paper reviews microtubule inhibitors in the treatment of pathologic angiogenesis.
93. P Mabeta MS Pepper 2009 A comparative study on the anti-angiogenic effects of DNA-damaging and cytoskeletal-disrupting agents Angiogenesis 12 81 90 19214765 1:CAS:528:DC%2BD1MXitlSqsLk%3D
94. X Ren M Dai LP Lin PK Li J Ding 2009 Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent Br J Pharmacol 156 1228 1238 19302593 1:CAS:528:DC%2BD1MXlsVWmtbc%3D
95. • Caballero S, Yang R, Grant MB, Chaqour B. Selective blockade of cytoskeletal actin remodeling reduces experimental choroidal neovascularization. Invest Ophthalmol Vis Sci. 2010. This paper demonstrates that inhibition of the actin cytoskeleton represents a potential therapeutic target in choroidal neovascularization.
96. JT Durham IM Herman 2009 Inhibition of angiogenesis in vitro: a central role for beta-actin dependent cytoskeletal remodeling Microvasc Res 77 281 288 19323981 1:CAS:528:DC%2BD1MXktlyqsL4%3D In this original report, a critical role for isoactin effectors in endothelial migration, morphogenesis, and survival is demonstrated.
97. ME Kutcher IM Herman 2009 The pericyte: cellular regulator of microvascular blood flow Microvasc Res 77 235 246 19323975 1:CAS:528: DC%2BD1MXktlyqs7g%3D This is a cogent review revealing the role of the microvascular pericyte in modulation of capillary structure and function.
98. J Bennett J Wilson D Sun B Forbes A Maguire 1994 Adenovirus vector-mediated in vivo gene transfer into adult murine retina Invest Ophthalmol Vis Sci 35 2535 2542 8163342 1:STN:280:DyaK2c3hs1Sqsg%3D%3D (Pubitemid 24137050)
99. C Jomary TA Piper G Dickson LA Couture AE Smith MJ Neal, et al. 1994 Adenovirus-mediated gene transfer to murine retinal cells in vitro and in vivo FEBS Lett 347 117 122 8033987 1:CAS:528:DyaK2cXlt1Kht7Y%3D (Pubitemid 24215377)
100. LM Hoffman AM Maguire J Bennett 1997 Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery Invest Ophthalmol Vis Sci 38 2224 2233 9344345 1:STN:280:DyaK1c%2FgtlSgsg%3D%3D (Pubitemid 27446939)
101. Q Li R Miller PY Han J Pang A Dinculescu V Chiodo, et al. 2008 Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential Mol Vis 14 1760 1769 18836574 1:CAS:528: DC%2BD1cXhtlSmurjP
102. K Mori P Gehlbach A Ando K Wahlin V Gunther D McVey, et al. 2002 Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathies Invest Ophthalmol Vis Sci 43 1610 1615 11980881 (Pubitemid 34462665)
103. V Biermann C Volpers S Hussmann A Stock H Kewes G Schiedner, et al. 2001 Targeting of high-capacity adenoviral vectors Hum Gene Ther 12 1757 1769 11560769 1:CAS:528:DC%2BD3MXntFWiurw%3D (Pubitemid 32911641)
104. S Wen S Graf PG Massey DA Dichek 2004 Improved vascular gene transfer with a helper-dependent adenoviral vector Circulation 110 1484 1491 15326058 1:CAS:528:DC%2BD2cXnt12ju7o%3D (Pubitemid 39238028)
105. E Vigne I Mahfouz JF Dedieu A Brie M Perricaudet P Yeh 1999 RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection J Virol 73 5156 5161 10233980 1:CAS:528:DyaK1MXjtFeqsro%3D (Pubitemid 29246779)
106. SA Nicklin SJ White CG Nicol DJ Von Seggern AH Baker 2004 In vitro and in vivo characterisation of endothelial cell selective adenoviral vectors J Gene Med 6 300 308 15026991 1:CAS:528:DC%2BD2cXjs1Oqt78%3D (Pubitemid 40228047)
107. P Li Y Liu J Maynard Y Tang A Deisseroth 2010 Use of adenoviral vectors to target chemotherapy to tumor vascular endothelial cells suppresses growth of breast cancer and melanoma Mol Ther 18 921 928 20179680 1:CAS:528: DC%2BC3cXitlais7k%3D
108. TJ Wickham DM Segal PW Roelvink ME Carrion A Lizonova GM Lee, et al. 1996 Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies J Virol 70 6831 6838 8794324 1:CAS:528: DyaK28XlslSqu78%3D (Pubitemid 26307394)
109. HJ Haisma J Grill DT Curiel S Hoogeland VW van Beusechem HM Pinedo, et al. 2000 Targeting of adenoviral vectors through a bispecific single-chain antibody Cancer Gene Ther 7 901 904 10880021 1:CAS:528:DC%2BD3cXks1KlsLw%3D (Pubitemid 30437291)
110. T Korn DM Nettelbeck T Volkel R Muller RE Kontermann 2004 Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv J Gene Med 6 642 651 15170735 1:CAS:528:DC%2BD2cXmtFSnsrg%3D (Pubitemid 40228080)
111. DM Nettelbeck AA Rivera J Kupsch D Dieckmann JT Douglas RE Kontermann, et al. 2004 Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA Int J Cancer 108 136 145 14618628 1:CAS:528:DC%2BD3sXps1entbk%3D (Pubitemid 37444456)
112. HJ Haisma GK Kamps A Bouma TM Geel MG Rots A Kariath, et al. 2010 Selective targeting of adenovirus to alphavbeta3 Integrins, VEGFR2 and Tie2 endothelial receptors by angio-adenobodies Int J Pharm 391 155 161 20211716 1:CAS:528:DC%2BC3cXltFCnsL4%3D In this report specific viral transduction of angiogenic endothelial cells can be accomplished via engineered adenobodies.
113. RT Hogg P Thorpe RD Gerard 2011 Retargeting adenoviral vectors to improve gene transfer into tumors Cancer Gene Ther 18 275 287 21183946 1:CAS:528:DC%2BC3cXhs1Wis7jN
114. M Chorny I Fishbein IS Alferiev O Nyanguile R Gaster RJ Levy 2006 Adenoviral gene vector tethering to nanoparticle surfaces results in receptor-independent cell entry and increased transgene expression Mol Ther 14 382 391 16807119 1:CAS:528:DC%2BD28XotFyksr8%3D (Pubitemid 44184965)
115. X Cai S Conley M Naash 2008 Nanoparticle applications in ocular gene therapy Vis Res 48 319 324 17825344 1:CAS:528:DC%2BD1cXhtlOmt7w%3D (Pubitemid 351179511)
116. R Farjo J Skaggs AB Quiambao MJ Cooper MI Naash 2006 Efficient non-viral ocular gene transfer with compacted DNA nanoparticles PLoS ONE 1 e38 17183666
117. ML Balestrieri C Napoli 2007 Novel challenges in exploring peptide ligands and corresponding tissue-specific endothelial receptors Eur J Cancer 43 1242 1250 17449238 1:CAS:528:DC%2BD2sXlt1ahsLo%3D (Pubitemid 46729702)
118. E Ruoslahti T Duza L Zhang 2005 Vascular homing peptides with cell-penetrating properties Curr Pharm Des 11 3655 3660 16305501 1:CAS:528:DC%2BD2MXhtFOrt7jI (Pubitemid 41630991)
119. HM Ellerby W Arap LM Ellerby R Kain R Andrusiak GD Rio, et al. 1999 Anti-cancer activity of targeted pro-apoptotic peptides Nat Med 5 1032 1038 10470080 1:CAS:528:DyaK1MXlslGqtLs%3D (Pubitemid 29439574)
120. J Mueller FC Gaertner B Blechert KP Janssen M Essler 2009 Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo Mol Cancer Res 7 1078 1085 19584266 1:CAS:528:DC%2BD1MXos1emtrg%3D
121. A Hajitou R Pasqualini W Arap 2006 Vascular targeting: recent advances and therapeutic perspectives Trends Cardiovasc Med 16 80 88 16546688 1:CAS:528:DC%2BD28XisF2iu78%3D
122. K Porkka P Laakkonen JA Hoffman M Bernasconi E Ruoslahti 2002 A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo Proc Natl Acad Sci USA 99 7444 7449 12032302 1:CAS:528: DC%2BD38XktlCktb0%3D (Pubitemid 34568710)
123. V Fogal KN Sugahara E Ruoslahti S Christian 2009 Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature Angiogenesis 12 91 100 19225898 1:CAS:528:DC%2BD1MXitlSqsLs%3D This paper describes the usefulness of an anti-NCL antibody, which specifically targets angiogenic endothelial cells.
124. • Binder C, Cashman SM, Read SP, Kumar-Singh R. Nuclear targeted delivery of macromolecules to retina and cornea. J Gene Med. 2011. This is a report demonstrating that large molecules and DNA transfer into a wide range of cell types can be accomplished via NCL-binding peptide conjugated to nanoparticles.
125. SA Kaliberov LN Kaliberova CR Stockard WE Grizzle DJ Buchsbaum 2004 Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer Mol Ther 10 1059 1070 15564138 1:CAS:528:DC%2BD2cXhtVSntrfL (Pubitemid 39625250)
126. X Bu T Quertermous 1997 Identification of an endothelial cell-specific regulatory region in the murine endothelin-1 gene J Biol Chem 272 32613 32622 9405477 1:CAS:528:DyaK1cXislensQ%3D%3D (Pubitemid 28011951)
127. BM Fadel SC Boutet T Quertermous 2000 Endothelial cell-specific regulation of the murine endothelin-1 gene J Cardiovasc Pharmacol 35 S7 11 10976773 1:CAS:528:DC%2BD3cXotlWrs7w%3D
128. G Mavria KJ Harrington CJ Marshall CD Porter 2005 In vivo efficacy of HSV-TK transcriptionally targeted to the tumour vasculature is augmented by combination with cytotoxic chemotherapy J Gene Med 7 263 275 15543524 1:CAS:528:DC%2BD2MXjtlamur8%3D (Pubitemid 40443755)
129. I Hodish R Tal A Shaish N Varda-Bloom S Greenberger A Rauchwerger, et al. 2009 Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK Cancer Biol Ther 8 424 432 19276657
130. JA Abraham JL Whang A Tumolo A Mergia J Friedman D Gospodarowicz, et al. 1986 Human basic fibroblast growth factor: nucleotide sequence and genomic organization EMBO J 5 2523 2528 3780670 1:CAS:528:DyaL2sXhtl2isQ%3D%3D
131. H Yamada E Yamada N Kwak A Ando A Suzuki N Esumi, et al. 2000 Cell Injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina J Cell Physiol 185 135 142 10942527 1:CAS:528: DC%2BD3cXmt1Ors7c%3D
132. SJ Leibovich PJ Polverini HM Shepard DM Wiseman V Shively N Nuseir 1987 Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha Nature 329 630 632 2443857 1:STN:280:DyaL1c%2FhsVagsQ%3D%3D (Pubitemid 17140112)
133. TA Gardiner DS Gibson TE de Gooyer VF de la Cruz DM McDonald AW Stitt 2005 Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy Am J Pathol 166 637 644 15681845 1:CAS:528:DC%2BD2MXitVGmsb8%3D (Pubitemid 40189058)
134. SA Vinores WH Xiao J Shen PA Campochiaro 2007 TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage J Neuroimmunol 182 73 79 17107717 1:CAS:528: DC%2BD2sXitlymsQ%3D%3D (Pubitemid 46039759)
135. MB Grant RN Mames C Fitzgerald EA Ellis M Aboufriekha J Guy 1993
136. LE Smith JJ Kopchick W Chen J Knapp F Kinose D Daley, et al. 1997 Essential role of growth hormone in ischemia-induced retinal neovascularization Science 276 1706 1709 9180082 1:CAS:528:DyaK2sXjvV2mt7g%3D (Pubitemid 27421979)
137. J Ruberte E Ayuso M Navarro A Carretero V Nacher V Haurigot, et al. 2004 Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease J Clin Invest 113 1149 1157 15085194 1:CAS:528:DC%2BD2cXjt1yis7c%3D (Pubitemid 38544100)
138. J Laterra M Nam E Rosen JS Rao K Lamszus ID Goldberg, et al. 1997 Scatter factor/hepatocyte growth factor gene transfer enhances glioma growth and angiogenesis in vivo Lab Invest 76 565 577 9111517 1:CAS:528:DyaK2sXjtVait7o%3D (Pubitemid 27176109)
139. N Umeda H Ozaki H Hayashi H Kondo H Uchida K Oshima 2002 Non-paralleled increase of hepatocyte growth factor and vascular endothelial growth factor in the eyes with angiogenic and nonangiogenic fibroproliferation Ophthalmic Res 34 43 47 11834884 1:CAS:528:DC%2BD38XhtVCnsL0%3D (Pubitemid 34136849)
140. KK Hirschi SA Rohovsky PA D'Amore 1998 PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10 T1/2 cells and their differentiation to a smooth muscle fate J Cell Biol 141 805 814 9566978 1:CAS:528:DyaK1cXivVGjtrc%3D (Pubitemid 28217923)
141. MS Seo N Okamoto MA Vinores SA Vinores SF Hackett H Yamada, et al. 2000 Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment Am J Pathol 157 995 1005 10980138 1:CAS:528:DC%2BD3cXmvFWqtb0%3D (Pubitemid 32109391)
142. PA Campochiaro BM Glaser 1985 Endothelial cells release a chemoattractant for retinal pigment epithelial cells in vitro Arch Ophthalmol 103 1876 1880 4074178 1:CAS:528:DyaL28XhtVOgsbc%3D (Pubitemid 16172027)
143. M Barczyk S Carracedo D Gullberg 2010 Integrins Cell Tissue Res 339 269 280 19693543 1:CAS:528:DC%2BD1MXhsVymtrvI
144. J Luna T Tobe SA Mousa TM Reilly PA Campochiaro 1996 Antagonists of integrin Alpha v Beta 3 inhibit retinal neovascularization in a murine model Lab Invest 75 563 573 8874387 1:CAS:528:DyaK28XmvFWms7s%3D (Pubitemid 26346806)
145. N Umeda S Kachi H Akiyama G Zahn D Vossmeyer R Stragies, et al. 2006 Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist Mol Pharmacol 69 1820 1828 16527907 1:CAS:528:DC%2BD28XlsFWktbw%3D (Pubitemid 43894298)
146. A Auricchio KC Behling AM Maguire EM O'Connor J Bennett JM Wilson, et al. 2002 Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents Mol Ther 6 490 494 12377190 1:CAS:528:DC%2BD38Xns1Kluro%3D (Pubitemid 35214870)
147. K Takahashi Y Saishin Y Saishin RL Silva Y Oshima S Oshima, et al. 2003 Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment FASEB J 17 896 898 12670875 1:CAS:528:DC%2BD3sXjsFantLc%3D
148. CC Lai WC Wu SL Chen X Xiao TC Tsai SJ Huan, et al. 2001 Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin Invest Ophthalmol Vis Sci 42 2401 2407 11527956 1:STN:280: DC%2BD3MrgsFOjtg%3D%3D (Pubitemid 32848872)
149. BJ Raisler KI Berns MB Grant D Beliaev WW Hauswirth 2002 Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or kringles 1-3 of angiostatin reduce retinal neovascularization Proc Natl Acad Sci USA 99 8909 8914 12072560 1:CAS:528:DC%2BD38XltF2htLk%3D (Pubitemid 34693657)
150. T Igarashi K Miyake K Kato A Watanabe M Ishizaki K Ohara, et al. 2003 Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model Gene Ther 10 219 226 12571629 1:CAS:528:DC%2BD3sXptF2hsA%3D%3D (Pubitemid 36204410)
151. T Takahashi T Nakamura A Hayashi M Kamei M Nakabayashi AA Okada, et al. 2000 Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells Am J Ophthalmol 130 774 781 11124297 1:CAS:528:DC%2BD3cXovFKgt7k%3D (Pubitemid 32000859)
152. M Hangai YS Moon N Kitaya CK Chan DY Wu KG Peters, et al. 2001 Systemically expressed soluble Tie2 inhibits intraocular neovascularization Hum Gene Ther 12 1311 1321 11440624 1:CAS:528:DC%2BD3MXltVersbw%3D (Pubitemid 32681845)
153. M Honda T Sakamoto T Ishibashi H Inomata H Ueno 2000 Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration Gene Ther 7 978 985 10849558 1:CAS:528:DC%2BD3cXjvFyis74%3D (Pubitemid 30386663)
154. P Gehlbach AM Demetriades S Yamamoto T Deering WH Xiao EJ Duh, et al. 2003 Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier Hum Gene Ther 14 129 141 12614564 1:CAS:528:DC%2BD3sXhtlyjtr0%3D (Pubitemid 36422598)
155. CM Lai M Brankov T Zaknich YK Lai WY Shen IJ Constable, et al. 2001 Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization Hum Gene Ther 12 1299 1310 11440623 1:CAS:528:DC%2BD3MXltVersb8%3D (Pubitemid 32681844)
156. J Tombran-Tink GG Chader LV Johnson 1991 PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity Exp Eye Res 53 411 414 1936177 1:CAS:528:DyaK3MXmsVyktrY%3D
157. K Mori P Gehlbach A Ando D McVey L Wei PA Campochiaro 2002 Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor Invest Ophthalmol Vis Sci 43 2428 2434 12091447 (Pubitemid 34700678)
158. K Mori P Gehlbach S Yamamoto E Duh DJ Zack Q Li, et al. 2002 AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization Invest Ophthalmol Vis Sci 43 1994 2000 12037010 (Pubitemid 34587052)
159. P Gehlbach AM Demetriades S Yamamoto T Deering EJ Duh HS Yang, et al. 2003 Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization Gene Ther 10 637 646 12692592 1:CAS:528:DC%2BD3sXivVWktbY%3D (Pubitemid 36553609)
160. HF Dvorak NS Orenstein AC Carvalho WH Churchill AM Dvorak SJ Galli, et al. 1979 Induction of a fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products J Immunol. 122 1 166 74 762415 1:CAS:528:DyaE1MXhtF2gsbk%3D (Pubitemid 9078536)